NeuroOne Medical Technologies Corporation (Nasdaq: NMTC), a medical technology company focused on surgical solutions for neurological disorders, announced today that Ron McClurg will retire as Chief Financial Officer effective June 30, 2026. McClurg will remain with the company as a Senior Advisor through December 31, 2026, to facilitate a smooth transition. Chris Volker, the company's current Chief Operating Officer and a CFA charterholder, will assume the role of CFO on a permanent basis. Additionally, David Wambeke, newly appointed Chief Business Officer, will take over many of Volker's previous responsibilities.
Dave Rosa, CEO of NeuroOne, expressed gratitude for McClurg's contributions over five years, stating, "Ron's retirement marks the culmination of a long and successful career, and we are grateful for his leadership, stewardship, and commitment to NeuroOne." Rosa highlighted Volker's deep experience across medtech, finance, strategy, and commercial operations, expressing confidence in his ability to build on the foundation established by McClurg.
Volker brings over 25 years of progressive leadership in the medical device industry, including senior roles at Abbott, Cardiovascular Systems, Inc. (CSI), and St. Jude Medical. At CSI, he served as Vice President & General Manager of International, overseeing international P&L and commercial expansion. Prior to CSI, he held executive roles at St. Jude Medical, including corporate finance positions reporting directly to the CFO. Volker began his career in healthcare investment banking at Dain Rauscher, focusing on financial analysis and mergers and acquisitions. He holds an MBA from The Wharton School of the University of Pennsylvania.
McClurg commented, "It has been a privilege to serve as NeuroOne’s CFO for over five years... I remain fully committed to supporting NeuroOne through this transition period." Volker added, "I am honored to take on the role of CFO... NeuroOne has built strong momentum, both in advancing our product pipeline and commercially."
The transition comes as NeuroOne continues to advance its technology platform, which includes four FDA-cleared product families: Evo Cortical Electrodes, Evo sEEG Electrodes, OneRF Ablation System (for brain), and OneRF Trigeminal Nerve Ablation System. The company is also engaged in research and development for drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs. More information is available at nmtc1.com.
This press release contains forward-looking statements regarding the CFO succession plan and other matters. These statements are subject to risks and uncertainties, including those described in the company's filings with the Securities and Exchange Commission. NeuroOne undertakes no obligation to update these statements.
